Advertisement
Activated parathyroid hormone/parathyroid hormone–related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone
L.M. Calvi,1 N.A. Sims,2 J.L. Hunzelman,1 M.C. Knight,1 A. Giovannetti,1 J.M. Saxton,1 H.M. Kronenberg,1 R. Baron,2 and E. Schipani1
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Calvi, L. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Sims, N. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Hunzelman, J. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Knight, M. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Giovannetti, A. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Saxton, J. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Kronenberg, H. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Baron, R. in: JCI | PubMed | Google Scholar
1Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA2Yale University, School of Medicine, New Haven, Connecticut, USA
Address correspondence to: E. Schipani, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, USA. Phone: (617) 726-3966; Fax: (617) 726-7543; E-mail: schipani@helix.mgh.harvard.edu.
Find articles by Schipani, E. in: JCI | PubMed | Google Scholar
Published February 1, 2001 - More info
J Clin Invest. 2001;107(3):277–286. https://doi.org/10.1172/JCI11296.
© 2001 The American Society for Clinical Investigation
Received: September 11, 2000; Accepted: December 18, 2000
-
Methods
Generation and identification of transgenic mice. The 2.3-kb fragment of the mouse α1(I) collagen promoter (14) was excised from the plasmid pJ251, kindly provided by Benoit de Crombrugge (University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA), by double digestion with XhoI/XbaI. The ends of this fragment were made blunt with Klenow polymerase and ligated to a blunt-ended BamHI site in the pcDNAI plasmid containing the cDNA that encodes the entire coding region of the human mutant PPR (HKrk-H223R) (12), placing the promoter fragment upstream of HKrk-H223R. Restriction endonuclease digestions and nucleotide sequence analysis confirmed the correct orientation of the construct (Figure 1a). Nucleotide sequence analysis also confirmed the presence of an in-frame stop codon and of the native Kozak consensus sequence upstream of the translation initiation codon. The construct insert, containing the 2.3-kb fragment of the mouse α1(I) collagen promoter, 1,880 bp encoding HKrk-H223R and 750 bp from the pcDNAI vector (which provides a splice sequence and the consensus polyadenylation signal absent in the cDNA encoding HKrk-H223R), was released from the vector by digestion with HindIII and ScaI (Figure 1a) and purified according to standard techniques. Microinjections into the pronucleus of fertilized oocytes were performed at the Massachusetts General Hospital Transgenic Facility (Boston, Massachusetts, USA). Founder mice of the FVB/N strain were mated with wild-type mice to establish individual transgenic lines. Genotyping and determination of the number of insertion sites of the transgene were performed as described (15). All studies performed were approved by the institutional animal care committee.
Figure 1Transgene construct and its expression. (a) Shown is the scheme of the transgene construct with the location of probes A and B for Southern blot analysis of genomic DNA. Locations of the translation initiation codon (ATG), the receptor mutation (H223R), and the stop codon (Stop) in the cDNA encoding the human PPR mutant, HKrk-H223R, are seen. Restriction sites for the enzymes HindIII, PvuII, and ScaI are also indicated. Oligonucleotide S was used as probe for Southern blot analysis of RT-PCR products, oligonucleotides S1 and A were used for RT-PCR of total RNA, and oligonucleotides S2 and A1 were used to generate the DT7 probe. (b) Southern blot analysis of the RT-PCR products with probe S: RT-PCR products from line not expressing the transgene (lanes 1 and 6), CL1 (lanes 2, 3, 7, and 8), and CL2 (lanes 4 and 9), with negative control in lane 5 and –RT controls in lanes 6–9. (c–h) In situ hybridization with the 35S-labeled DT7 cRNA in serial section of decalcified proximal tibia of newborn CL2 mouse (c and d),and a wild-type littermate (g and h). In the high-magnification images from 2-week-old CL2 mutant (e and f), the arrow indicates the periosteal surface. (i) In situ hybridization with the 35S-labeled PPR cRNA in a section of decalcified proximal tibia of a newborn wild-type mouse. All sections were counterstained with hematoxylin and eosin; bright-field (c, e, g) and dark-field (d, f, h, i) views are shown.
Assessment of transgene expression. To assess the expression of the mutant PPR transgene in bone, total RNA was extracted from newborn calvaria using TRIzol reagent (Life Technologies, Gaithersburg, Maryland, USA). Total RNA was reversed transcribed into single-stranded DNA using the pcDNAI-specific reverse primer A (5′-TTCCACCACTGCCTCCCATTCATC-3′) and the Omniscript Reverse Transcriptase kit (QIAGEN Inc., Valencia, California, USA). PCR was performed using the same reverse primer A and the forward primer S1 (5′-CACCTGCCCTGCTACAGGAAGAG-3′) (Figure 1a) with the following conditions: 94°C for 1 minute, 58°C for 45 seconds, 72°C for 1 minute, and an additional 10 minutes at 72°C at the end of the 35 cycles. In addition, the PCR products were determined by Southern blot analysis using the 32P-labeled oligonucleotide S (5′-TGACATAGTGGATGGACAGATGG-3′). To confirm transgene expression by in situ hybridization, a 596-bp probe (DT7) was generated by PCR amplification of the pcDNAI vector sequence in the transgene construct using the reverse primer A1 (5′-TAATACGACTCACTATAGGGCGATAAACAAGTTAACAACAACAAT-3′) and the forward primer S2 (5′-CTTTGTGAAGGAACCTTACT-3′) (Figure 1a). The A1 reverse primer sequence also includes the T7 RNA polymerase-binding site. The PCR conditions were as follows: 94°C for 1 minute, 58°C for 45 seconds, 72°C for 1 minute, and an additional 10 minutes at 72°C at the end of the 45 cycles.
Serology. Serum was collected at 1 month of age for ionized calcium and PTH-level determination. Ionized calcium was measured by the Ciba-Corning 634 Ca++/pH analyzer (Ciba-Corning Diagnostics Corp., Medfield, Massachusetts, USA). Intact immunoreactive PTH was measured in duplicate using ELISA (Immutopics Inc., San Clemente, California, USA), which uses two affinity-purified polyclonal Ab’s raised to peptides common to rat and mouse PTH. The first Ab recognizes epitopes within the midregion/carboxy-terminal portion of the peptide (region 39–84), while the second Ab, conjugated to horseradish peroxidase for detection, recognizes epitopes in the amino-terminal region (region 1–34). Statistical analysis was performed using the Student’s t test, and P values less than 0.05 were accepted as significant.
Sample preparation and histologic analysis. For histologic analysis, transgenic mice and sex-matched wild-type littermates were sacrificed by cervical dislocation at birth, 1, 2, 4, and 12 weeks of age. Tissues from transgenic and wild-type mice were fixed and stored as described (15). In selected cases, hindlimbs and/or skulls were decalcified (15), and paraffin blocks were prepared by standard histological procedures. For selected samples, tartrate-resistant acid phosphatase (TRAP) staining was performed using a Sigma Chemical Co. acid phosphatase detection kit (St. Louis, Missouri, USA).
Histomorphometry. Tibiae and calvaria were collected for histomorphometric analysis at 2, 6, and 12 weeks of age. For dynamic histomorphometry, 12-week-old animals were injected intraperitoneally with fluorochromes: calcein (2 mg/ml, Sigma Chemical Co.) and demeclocycline (2 mg/ml, Sigma Chemical Co.) were injected 3 and 10 days before sacrifice, respectively. Bones were fixed and embedded in methyl methacrylate resin as described previously (16). Five-micrometer sections were stained with toluidine blue or coverslipped unstained, and histomorphometric analysis was performed with the Osteomeasure system (Osteometrics Inc., Atlanta, Georgia, USA) using standard procedures (17). Tibial sections were measured in the proximal metaphysis beginning 340 μm below the chondro-osseous junction. Tibial cortical thickness and periosteal mineral appositional rates were measured beginning 680 μm from the chondro-osseous junction on the anterofibular side. Coronal sections of the parietal bone were measured immediately frontal to the interparietal bone, excluding 300 μm on either side of the sagittal suture. Statistical analysis was performed using ANOVA, with P values less than 0.05 accepted as significant; error bars represent ± SEM.
In situ hybridization. In situ hybridizations were performed as described (15) using complementary 35S-labeled riboprobes (complementary RNAs and cRNAs) transcribed from the plasmids encoding rat alkaline phosphatase (nucleotides 1–241; GenBank accession no. J03572), collagenase 3 (18), human pro-alpha 1(I) chain of type I procollagen (nucleotides 2361–3347; GenBank accession no. K01228), mouse 92-kDa type IV collagenase or MMP-9 (nucleotides 1945–2266), mouse osteopontin (nucleotides 157–1144; GenBank accession no. X14882), rat PPR (nucleotides 1–2065; GenBank accession no. M77184), and rat TRAP (nucleotides 1–832; GenBank accession no. M76110). In addition, the complementary 35S-labeled riboprobe transcribed from the DT7 PCR product was used to detect expression of the transgene mRNA.
Analysis of bromodeoxyuridine incorporation. Mutant and transgenic mice at 1 and 2 weeks of age were injected intraperitoneally with 100 μg bromodeoxyuridine (BrdU)/12 μg fluorodeoxyuridine (FdU) per gram of body weight 2 hours before sacrifice. After sacrifice, hindlimbs were dissected, fixed, decalcified, and embedded in paraffin, and longitudinal sections across the tibia and femur were obtained. To identify actively proliferating cells, nuclei that had incorporated BrdU were detected using a Zymed BrdU immunostaining kit (Zymed Laboratories Inc., South San Francisco, California, USA). For each section, high-power field images of the primary spongiosa were photographed. All BrdU-positive (black) and BrdU-negative (pink) nuclei in this zone were counted. One or two nonconsecutive sections were counted for each of two or three wild-type and two or three transgenic specimens at each time point. To assess proliferation rates in periosteal cells, all BrdU-positive and BrdU-negative nuclei were counted in two high-power field (×400) images from equivalent portions of the lateral periosteum.
Determination of apoptotic osteoblasts in vivo. Apoptotic osteoblasts were detected in sections of decalcified tibiae of 2-week-old transgenic and wild-type littermates by the terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) reaction using reagents from the ApopTag Plus Peroxidase In Situ Detection Kit (Intergen Co., Purchase, New York, USA). The sections were counterstained with methyl green. In each TUNEL-labeling assay, sections of weaned rat mammary tissue were used as positive control. Negative controls were prepared by omitting the transferase. As in the analysis of BrdU incorporation, two high-power field images of the primary spongiosa were photographed for each animal. All positive (brown) and negative (green) nuclei in this zone were counted. One section was counted for each of four wild-type and five transgenic specimens.
-
Results
Generation, identification, and gross phenotype of transgenic mice. Two transgenic lines (CL1 and CL2) expressing the constitutively active human PPR, HKrk-H223R (12), under the control of the 2.3-kb fragment of the mouse α1(I) collagen promoter (14) were established. Founder CL1 was shown by Southern blot analysis to carry only one copy of the transgene, while founder CL2 carried several copies (data not shown).
PCR analysis of reverse-transcribed RNA extracted from newborn calvaria revealed specific expression of the transgene. Southern blot analysis of PCR products showed a 280 bp–specific band, not present in the –reverse transcriptase (–RT) controls (Figure 1b); an additional 350-bp band was present in both +RT and –RT samples (Figure 1b), presumably as a result of amplification of genomic DNA contaminating the total RNA preparation. Expression of the transgene was detected in both lines. Relative levels of expression in the two lines were assessed by Northern blot analysis using probe DT7 and were noted to be many fold higher for the CL2 line (data not shown). For this line, transgene expression was also detected by in situ hybridization at birth and postnatally and localized to osteoblastic and stroma-like cells in the trabecular bone compartment, as well as the endosteal and periosteal surfaces of mutant bones of all ages tested (Figures 1, c–h, and data not shown). The pattern of expression of the transgene in mutant animals overlapped with that of the native PPR in wild-type animals in the osseous regions of the bone, but was slightly more diffuse, consistent with targeting by the 2.3-kb fragment of the mouse α1(I) collagen gene promoter (Figure 1i). In addition, low-level expression of the transgene was noted in the growth plate and at the site of attachment of tendons in sections from newborn transgenic mice (Figure 1d), although the characteristic pattern of high-level expression of the PPR in the early hypertrophic region of the growth plate was not seen (Figure 1i). No transgene expression was seen in multinucleated cells in the bones of CL2 transgenic animals (data not shown). Expression of the transgene could not be detected by in situ hybridization in the CL1 line (data not shown).
At birth, transgenic mice were indistinguishable from wild-type littermates. At 2 weeks of age, hemizygous transgenic mice from the CL1 line were very similar to normal mice, while homozygous mice had shortening of the limbs and the tail. Consistent with the higher level of transgene expression, 2-week-old hemizygous animals from the CL2 line were clearly smaller and had shorter limbs than sex-matched control littermates (data not shown). Therefore, homozygous animals from the CL1 line and hemizygous animals from the CL2 line were studied after birth. Both transgenic lines showed qualitatively similar skeletal changes at all stages of postnatal development studied in both males and females. In addition, consistent with high levels of expression of the transgene in odontoblasts, CL2 mice had abnormally large incisors, which erupted normally (data not shown).
Serology. There were no differences in ionized calcium between normal and transgenic mice of both lines (ionized Ca2++, millimoles per liter: wild-type, n = 12, 1.30 ± 0.02; CL1, n = 4, 1.33 ± 0.03, P = 0.624; CL2, n = 6, 1.29 ± 0.03, P = 0.929). Intact PTH measurements showed a slightly decreased PTH level in mutant compared with normal mice (PTH in picograms per milliliter: wild-type, n = 38, 35.3 ± 3.3; CL2, n = 18, 22.7 ± 4.4, P < 0.05).
Trabecular bone. Histologic analysis of the skeleton in CL2 mice revealed an increase in trabeculation of the metaphyseal regions of the long bones. This trabeculation had a disorganized, reticular pattern, and it extended into the diaphysis with partial obliteration of the bone marrow cavity (Figure 2, g–h). The increase was present in sections from 1-week-old animals (data not shown), was very dramatic at 2 weeks (Figure 2, a and c), and persisted in adulthood (Figure 2, d and f–h). In 1-week-old and 2-week-old mutants, the trabeculae close to the growth plate contained remnants of cartilage matrix as in a typical primary spongiosa, while no residual cartilage matrix was noted in the trabeculae that extended into the medullary cavity, suggesting that these trabeculae were the result of increased de novo bone formation and increased bone remodeling, rather than of defective osteoclast bone-resorbing activity (data not shown). The trabeculae were normally mineralized, as shown by Von Kossa staining (Figure 2, a–f). Histomorphometric analysis confirmed the increase in trabecular number and volume (Figure 2, l and m). Trabecular thickness was unchanged (data not shown). In the transgenic mice, the spaces among the trabeculae, usually occupied by hematopoietic cells in wild-type animals, were populated mainly by stroma-like cells with a fibrotic appearance (Figure 2, i and j), as confirmed by histomorphometric analysis (Figure 2n). A similar but milder phenotype was noted in CL1 mice (Figure 2, b, e, l, and m).
Figure 2Histology and histomorphometry of trabecular bone. (a–f) Histologic sections of undecalcified proximal tibia of 2-week-old (a–c) and 6-week-old (d–f) wild-type (a and d), CL1 (b and e), and CL2 (c and f) mice stained by the method of Von Kossa. (g–j) Histologic sections, stained with hematoxylin and eosin, of decalcified proximal tibia from 12-week-old wild-type (g) and CL2 (h) littermates. In the high-power images from the proximal tibia of 12-week-old wild-type (i) and CL2 transgenic (j) littermates, the metaphyseal area is shown. (k–p) Histomorphometric analysis of wild-type (light blue), CL1 (magenta), and CL2 (dark blue) littermates. Ages of animals are indicated on the x-axis. AP < 0.05, BP < 0.01, CP < 0.005. Error bars represent the SEM.
To assess whether the increased trabecular bone volume seen in mutant mice could be secondary to augmented osteoblast activity, dynamic histomorphometry was performed. In 12-week-old animals, there was a 6.5-fold increase in trabecular bone formation rate compared with wild-type littermates (P < 0.05, Figure 2p). Trabecular mineral apposition rate, an index of osteoblast function, was also increased by 30% in transgenic mice compared with normal littermates (wild-type, micrometers per day: 0.968 ± 0.08; CL2: 1.253 ± 0.04, P < 0.05). In addition, histomorphometric analysis showed a dramatic increase in osteoblast number (Figure 2o).
In situ hybridization analysis was performed to characterize the degree of differentiation of the stroma-like cells in the trabecular compartment of CL2 transgenic mice. Osteocalcin mRNA was expressed strongly by the cuboidal cells lining the trabeculae (Figure 3, f, k, and p), suggesting they are fully mature osteoblasts (19). In addition, alkaline phosphatase (Figure 3, a, b, g, and l), collagen I (Figure 3, c, h, and m), collagenase 3 (Figure 3, d, i, and n), osteopontin (Figure 3, e, j, and o) mRNAs were expressed heterogeneously by the stroma-like cells among the trabeculae, suggesting that these cells belong to the osteoblast lineage.
Figure 3In situ hybridization analysis of trabecular bone. In situ hybridization with the 35S-labeled alkaline phosphatase (a, b, g, l), collagen I (c, h, m), collagenase 3 (d, i, n), osteopontin (e, j, o), and osteocalcin (f, k, p) cRNAs in serial sections of decalcified proximal tibia from 2-week-old CL2 mouse. Higher-magnification images of the trabecular area are shown (g–p). The sections were counterstained with hematoxylin and eosin; bright-field (a, l–p) and dark-field (b–k) views are shown.
To assess whether changes in proliferation rate contributed to the expansion of the osteoblastic population, BrdU incorporation rates were measured in the trabecular compartment of 2-week-old wild-type and CL2 mutant animals. Proliferation rates were increased by 30% in transgenic animals (wild-type percentage 14.5 ± 1.6; CL2 18.7 ± 0.8, P < 0.05). An even larger increase in proliferation rate was seen at 1 week of age (wild-type percentage 16.4 ± 3.3; CL2 32.3 ± 5.8, P < 0.05). Conversely, in the same areas, the proportion of osteoblastic cells undergoing apoptosis, as detected by TUNEL labeling, was decreased in CL2 transgenic mice (0.4% ± 0.1) compared with wild-type littermates (1.6% ± 0.4, P < 0.05), suggesting that changes in both proliferation and apoptosis rates contributed to the expansion of the osteoblast pool.
Histologic analysis of the long bones from mutant mice showed a dramatic increase in multinucleated cells, which was confirmed by histomorphometry (Figure 2k). Many of these multinucleated cells expressed high levels of TRAP mRNA and protein, as shown by in situ hybridization analysis (Figure 4, a–d) and specific enzymatic staining for TRAP activity (Figure 4e) and were therefore mature osteoclasts.
Figure 4Osteoclast number and function. (a–d) In situ hybridization with the 35S-labeled TRAP cRNA in serial sections of decalcified proximal tibia of 2-week-old wild-type (a and b) and CL2 (c and d) littermates. The sections were counterstained with hematoxylin and eosin; bright-field (a and c) and dark-field (b and d) views are shown. (e and f) High-power (×200) light microscopy of enzymatic staining for TRAP activity in sections of decalcified proximal tibia from a 2-week-old CL2 mouse, focusing on the metaphyseal trabecular bone (e) and the diaphyseal cortical bone (f); the arrow indicates one of the TRAP-positive multinucleated cells. Sections were counterstained with methyl green.
Cortical bone. Transgenic cortical bone in both CL1 and CL2 mice was histologically normal at birth (Figure 1, c and g, and data not shown). By 12 weeks of age, the predominant histological feature of the mutant CL2 cortical bone was its decreased thickness (Figure 5, c–d), confirmed by histomorphometry (Figure 5e). No significant difference in cortical thickness could be observed in the CL1 mice, consistent with the milder skeletal phenotype of this line. Starting at 1 month of age in both CL1 and CL2 animals, the cortical bone was porous rather than compact (Figure 5, a–d), suggesting an increased bone-modeling/remodeling process at the endosteal surface. A large number of osteoclasts were present in the cortical bone of the mutant mice (Figure 4f).
Figure 5Analysis of cortical bone. (a–d) Histologic sections of cortical bone from tibial mid-diaphysis of 8-week-old wild-type (a) and CL1 transgenic (b) littermates and 12-week-old wild-type (c) and CL2 transgenic (d) littermates. (e and f) Histomorphometric analysis performed in 12-week-old wild-type (light blue) and CL2 (dark blue) littermates. AP < 0.05, BP < 0.01. Error bars represent the SEM. MAR, mineral apposition rate. (g–r) High-power (×200) light microscopy images of the mid-diaphysis of in situ hybridization with the 35S-labeled alkaline phosphatase (g–j), collagen I (k–n), and osteocalcin (o–r) cRNAs in serial sections of decalcified proximal tibia of 2-week-old wild-type (g, h, k, l, o, p) and CL2 (i, j, m, n, q, r) mice; sections were counterstained with hematoxylin and eosin. Bright-field (g, i, k, m, o, q) and dark-field (h, j, l, n, p, r) views are shown. The arrow indicates the periosteal surface.
Since periosteal mineral apposition rate is a major determinant of cortical bone formation and maintenance, this parameter was measured in 12-week-old wild-type and CL2 transgenic animals by dynamic histomorphometry. In striking contrast to the significant increase in trabecular mineral apposition rate seen in the transgenic mice, no periosteal mineral apposition rate could be measured in tibiae from the same transgenic animals (Figure 5f). To assess whether the presence of the transgene in periosteal cells also modified their proliferation rate, BrdU incorporation rate was measured in the periosteum. In contrast to the significant increase in proliferation rate seen in cells in the trabecular compartment, a 50% decrease in BrdU incorporation was measured in the periosteal compartment of CL2 transgenic mice compared with wild-type littermates (wild-type 6.8 ± 1.5%; transgenic 3.5 ± 0.5%, P < 0.05). Characterization of the transgenic periosteal cells by in situ hybridization revealed a decreased level of expression of osteoblast markers such as alkaline phosphatase, collagen I and osteocalcin, in comparison with wild-type periosteal cells (Figures 5, e–p). The same markers appeared to be well expressed by the endosteal cells in both wild-type and mutant bones (Figure 5, e–p). Taken together, these data suggest that transgene expression has an inhibitory effect in the periosteum, but not in the endosteum.
Increased bone remodeling on the endosteal surface and increased “porosity” was also observed in compact bone in the skull, which is formed by intramembranous ossification rather than the endochondral process by which long bones are formed. While calvarial thickness was unchanged in transgenic mice (wild-type thickness, micrometers: 86.0 ± 4.5; CL2: 87.4 ± 5.5), the transgenic calvaria were considerably more porous and contained more woven bone than wild-type calvaria in the same area (Figure 6, a and b). Quantification revealed an increase in the ratio of marrow space to bone volume in the calvarial bone in transgenic mice (Figure 6c). As observed in long bones, bone formation rate on the calvarial endosteal surfaces was significantly increased (Figure 6d), whereas the bone-formation rate on the calvarial periosteal surfaces was reduced (Figure 6e). The calvarial bone of CL2 mice also contained small areas of fibrosis in marrow spaces distant from the sagittal suture.
Figure 6Skull histology and histomorphometry. (a and b) Sections of skulls from 12-week-old wild-type (a) and CL2 (b) littermates, stained with the method of Von Kossa. Arrows show the endosteal surfaces. (c–e) Histomorphometric analysis of the skull from wild-type (light blue) and CL2 (dark blue) littermates at 12 weeks of age. AP < 0.05, BP < 0.01. Error bars represent the SEM.
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)